ARO IAV
Alternative Names: ARO-IAVLatest Information Update: 31 May 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antivirals; Small interfering RNA
- Mechanism of Action Influenza A virus M1 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Influenza A virus infections